Recent Updates
Recently added Catalysts

BMS-986482

Phase 1

Advanced Solid Tumors | Small molecule | Oncology |Bristol-Myers Squibb Company|Last Updated: Feb 3, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment413
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06697197A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid TumorsPHASE1 RECRUITING 413 — — Feb 17, 2025Jan 5, 2029Feb 3, 202621 United States, Belgium +7
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)
Up to 135 days post last treatment visit
Number of participants with Serious AEs (SAEs) as assessed by NCI-CTCAE v5.0
Up to 135 days post last treatment visit
Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria as assessed by NCI-CTCAE v5.0
Up to Day 28
Number of participants with AEs leading to discontinuation as assessed by NCI-CTCAE v5.0
Up to 135 days post last treatment visit
Number of deaths as assessed by NCI-CTCAE v5.0
Through study completion (Up to 4 years)
Secondary Endpoints
Concentration at the end of infusion (Cmax)
Up to 135 days post last treatment visit
Time of maximum observed concentration (Tmax)
Up to 135 days post last treatment visit
Area under the concentration-time curve in one dosing interval (AUC(TAU))
Up to 135 days post last treatment visit
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part 1AEXPERIMENTAL -
Part 1B1EXPERIMENTAL -
Part 1B2EXPERIMENTAL -
Part 1B3EXPERIMENTAL -
Part 1CEXPERIMENTAL -
Part 2AEXPERIMENTAL -
Part 2B1EXPERIMENTAL -
Part 2B2EXPERIMENTAL -
Part 2B3EXPERIMENTAL -
Interventions
NameTypeDescription
BMS-986482DRUGSpecified dose on specified days
Nivolumab and rHuPH20DRUGSpecified dose on specified days
Nivolumab/relatlimab/rHuPH20DRUGSpecified dose on specified days
BevacizumabDRUGSpecified dose on specified days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites21

Inclusion Criteria: * All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical...

Countries:United StatesBelgiumDenmarkFranceGreeceItalyNetherlandsSpainSweden
Unlock Eligibility Criteria
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06697197primaryCompletionDate: changed
LOWMay 24, 2026NCT06697197studyFirstPostDate: changed